Furthermore, there is an unmet need to translate theoretical information into clinical practice which has been done, for example, with the use of adavosertib, an WEE1 inhibitor, to increase response in DLBCL patients. This evidence concerns the gene WEE1 and diffuse large B-cell lymphoma.